Muhammed Muhittin Er

7PUBLICATIONS
29CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Nutrigenomics and personalised nutritionToxicology (incl. clinical toxicology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jun 26, 2026
Early PSA Decline Predicts Survival Outcomes in Metastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors: A Retrospective Single-Center Study.

|May 27, 2026
Prognostic and Treatment-Specific Predictive Implications of HER2 Expression in RAS Wild-Type Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Study.

|Jul 30, 2025
Prognostic Role of Inflammatory and Nutritional Indices in NSCLC Patients Treated with Immune Checkpoint Inhibitors: Retrospective, Multicenter, Turkish Oncology Group Study of Overall and Elderly Populations.

Ozkan Alan, Tugba Akın Telli, Sinem Akbas

|Mar 13, 2024
The effect of concomitant beta-blocker use on survival in patients with metastatic renal cell carcinoma treated with a vascular endothelial growth factor receptor inhibitors in the first line.

Mustafa Korkmaz, Melek Karakurt Eryılmaz, Mehmet Zahid Koçak

|Sep 22, 2023
Is the Prognostic Nutritional Index a Prognostic Marker for the Survival of Patients with Lymph-Node Positive Stage II-III Gastric Cancer Who Receive Adjuvant Chemotherapy?

Mustafa Korkmaz, Melek Karakurt Eryılmaz, Muhammed Muhiddin Er

|Feb 10, 2023
Ribociclib-induced hepatotoxicity.

Muhammed Muhiddin Er, Murat Araz, Engin Hendem

Pageof 2

Frequent Collaborators

5 joint publications

Mehmet Artaç

4 joint publications

Melek Karakurt Eryılmaz

3 joint publications

Engin Hendem

3 joint publications

Mustafa Korkmaz